Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Erythrocyte, Cell Culture
DISEASE(S): Sickle Cell Anemia
SUBMITTER: Masaya Usui
LAB HEAD: Akihiro Ito
PROVIDER: PXD033536 | Pride | 2023-03-11
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
210305_QE_18_152_Shirai_HUDEP_HbFI_2uL.raw | Raw | |||
F211363.dat | Other | |||
F211363.mgf | Mgf | |||
F211363.mzid.gz | Mzid |
Items per page: 5 1 - 4 of 4 |
Takase Shohei S Hiroyama Takashi T Shirai Fumiyuki F Maemoto Yuki Y Nakata Akiko A Arata Mayumi M Matsuoka Seiji S Sonoda Takeshi T Niwa Hideaki H Sato Shin S Umehara Takashi T Shirouzu Mikako M Nishigaya Yosuke Y Sumiya Tatsunobu T Hashimoto Noriaki N Namie Ryosuke R Usui Masaya M Ohishi Tomokazu T Ohba Shun-Ichi SI Kawada Manabu M Hayashi Yoshihiro Y Harada Hironori H Yamaguchi Tokio T Shinkai Yoichi Y Nakamura Yukio Y Yoshida Minoru M Ito Akihiro A
Nature communications 20230112 1
Sickle cell disease (SCD) is a heritable disorder caused by β-globin gene mutations. Induction of fetal γ-globin is an established therapeutic strategy. Recently, epigenetic modulators, including G9a inhibitors, have been proposed as therapeutic agents. However, the molecular mechanisms whereby these small molecules reactivate γ-globin remain unclear. Here we report the development of a highly selective and non-genotoxic G9a inhibitor, RK-701. RK-701 treatment induces fetal globin expression bot ...[more]